Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

The biotech handily beat the average analyst estimate for profitability. Investors were surely happy about this, but they might have been more impressed by the sales of a promising drug that recently won approval.

Why Biogen Stock Leaped Nearly 5% Higher Today

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.

Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales

Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quarter of 2024, Biogen reported a revenue of $2.29 billion, which slightly missed expectations by $30 million.

Biogen Q1 2024 results surpass expectation despite revenue decline

New product launches progressing well, Biogen says, but total sales fall short of analyst expectations

Biogen first-quarter profit tops estimates as Alzheimer's drug uptake improves

Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition.

Biogen beats quarterly profit estimates, Alzheimer's drug sales jump

Alzheimer's drug Leqembi brought in in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.

Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up

Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and could help Biogen stock reverse a recent downtrend.

Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.

What's in Store for Biogen (BIIB) This Earnings Season?

Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

BASEL, Switzerland--(BUSINESS WIRE)--Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease. As part of the agreement, Biogen will licence KonectomTM to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution. Through this collaboration, Indivi.

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease

The European Union's medicines regulator did not mention Eisai and Biogen's Alzheimer's drug in its notes and recommendations on Friday.

EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes

NEW YORK--(BUSINESS WIRE)---- $BIIB #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB). Investors who purchased Biogen Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIIB. Investigation Details: On February 14, 2024, Biogen disclosed receipt of a subpoena from the U.S. Department of Justice.

Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)

Biogen Inc. (BIIB) reachead $219.40 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.

Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today

Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored) Are you ready for retirement?

$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?

Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?

Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.

Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know

NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB

AbCellera Biologics

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. “We are excited to work with Bio.

News for Biogen Stock (BIIB)